SCHEMBL31268767

SCHEMBL31268767

COc1cccc(Cn2c(-c3ccc(OCCC(C)C(=O)O)cc3Cl)nc3c(OC4(C)CC4)ncnc32)c1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PPARG P37231 3/20 0.37
▸ USP2 O75604 9/20 0.36
▸ CYP1A2 P05177 9/20 0.36
▸ CYP3A4 P08684 9/20 0.36
▸ CYP2C9 P11712 9/20 0.36
▸ CYP2C19 P33261 9/20 0.36
▸ ALDH1A1 P00352 5/20 0.35
▸ LMNA P02545 4/20 0.35
▸ MAPK1 P28482 2/20 0.35
▸ TP53 P04637 2/20 0.35
▸ HSD17B10 Q99714 1/20 0.35
▸ CYP2D6 P10635 2/20 0.35
▸ MEN1 O00255 3/20 0.35
▸ KMT2A Q03164 3/20 0.35
▸ TLR7 Q9NYK1 1/20 0.35
▸ ALOX15 P16050 1/20 0.35
▸ CCR2 P41597 1/20 0.34
▸ PLA2G2A P14555 1/20 0.34
▸ TSHR P16473 5/20 0.34
▸ HTR6 P50406 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31269322 1.00 PPARG (0.37) PPARGUSP2CYP1A2CYP3A4CYP2C9
SCHEMBL30983500 0.93 CNR1 (0.35) PPARGLMNAMEN1KMT2ATLR7
SCHEMBL30983374 0.93 CNR1 (0.35) PPARGLMNAMEN1KMT2ATLR7
SCHEMBL30983474 0.93 CNR1 (0.35) PPARGLMNAMEN1KMT2ATLR7
SCHEMBL31269301 0.92 S1PR1 (0.35) CYP1A2CYP3A4CYP2C9CYP2C19MAPK1
SCHEMBL31269306 0.92 PIK3CD (0.32) PPARGKMT2APIK3CD
SCHEMBL31269103 0.92 ALOX5AP (0.33) KMT2APIK3CD
SCHEMBL31268741 0.92 PIK3CD (0.32) PPARGPIK3CD
SCHEMBL31268989 0.91 S1PR1 (0.40) PPARGALDH1A1LMNAKMT2AHTR6
SCHEMBL31268822 0.91 SCN1A (0.35) KMT2ATLR7PIK3CD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4689155-A1 USE OF INHIBITORS TO INCREASE EFFICIENCY OF CRISPR/CAS INSERTIONS Astrazeneca AB (SE) 2026-02-11 — — EP disclosed
WO-2024201368-A1 USE OF INHIBITORS TO INCREASE EFFICIENCY OF CRISPR/CAS INSERTIONS ASTRAZENECA AB (SE) 2024-10-03 — — WO disclosed
Send feedback